Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pharma-Bio Serv (PBSV) Income from Continuing Operations (2016 - 2026)

Pharma-Bio Serv filings provide 17 years of Income from Continuing Operations readings, the most recent being 32860.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 284.96% to 32860.0 in Q1 2026 year-over-year; TTM through Jan 2026 was 85697.0, a 82.8% increase, with the full-year FY2025 number at 100463.0, up 87.08% from a year prior.
  • Income from Continuing Operations hit 32860.0 in Q1 2026 for Pharma-Bio Serv, up from 102.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 526242.0 in Q3 2023 to a low of 309194.0 in Q3 2024.
  • Median Income from Continuing Operations over the past 5 years was 32860.0 (2026), compared with a mean of 86004.94.
  • Biggest five-year swings in Income from Continuing Operations: crashed 163.48% in 2024 and later soared 284.96% in 2026.
  • Pharma-Bio Serv's Income from Continuing Operations stood at 173379.0 in 2022, then crashed by 127.19% to 47148.0 in 2023, then soared by 134.17% to 16111.0 in 2024, then plummeted by 100.63% to 102.0 in 2025, then soared by 32315.69% to 32860.0 in 2026.
  • The last three reported values for Income from Continuing Operations were 32860.0 (Q1 2026), 102.0 (Q4 2025), and 213808.0 (Q3 2025) per Business Quant data.